Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies
Summary
Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of companys proprietary CyTAC and TicTAC platforms.Phase 1 trial of STX-0712 to assess safety and preliminary antitumor activity of novel CCR2-CyTAC therapy in patients with CMML.BOSTON, April 9, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series A financing that included participation from five new investors Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), and The Leukemia & Lymphoma Society Therapy Acceleration Program\xae as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Sant\xe9 Ventures, Astellas Venture Management, and Alexandria Venture Investments. Additionally, the funding will support the generation of new development candidates, including a novel, first-in-class mast cell depletor for immunological diseases, initiation of new discovery programs targeting pathogenic cells, further pipeline expansion, and exploration of new applications for the CyTAC and TicTAC platforms.STX-0712 is designed to selectively eliminate CCR2-positive malignant monocytes in patients with advanced hematologic malignancies, with an initial focus on CMML. Part B will further evaluate safety, tolerability, recommended Phase 2 dose and preliminary antitumor activity of STX-0712.Our team is thrilled to initiate this first-in-human clinical trial of STX-0712, marking a significant step forward in our mission to develop innovative therapies for patients with high unmet medical needs, said Sergio Santillana MD, Chief Medical Officer. By directly depleting the CCR2-positive malignant monocytes driving CMML, STX-0712 has the potential to offer a highly specific and targeted therapy for patients who currently have limited treatment options available. This trial represents an important milestone for Solu Therapeutics as we work to bring novel and potentially more effective targeted therapies to patients with CMML and other hematologic malignancies.In December 2024, Solu Therapeutics presented preclinical data at the 2024 American Society of Hematology (ASH) Annual Meeting showing robust ex-vivo activity of STX-0712 against CCR2-positive monocytes in CMML patient samples.